Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23193744 | 0.90 | ALDH1A1 (0.64) | ALDH1A1HPGDHSD17B10MEP1BCA2 | |
| SCHEMBL165384 | 0.87 | PSIP1 (0.57) | ALDH1A1HPGDHSD17B10MEP1BCA2 | |
| SCHEMBL20709277 | 0.86 | ALDH1A1 (0.50) | ALDH1A1HPGDHSD17B10HTTKDM4E | |
| SCHEMBL27450030 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CA2GAALMNAKMT2A | |
| SCHEMBL10061269 | 0.84 | CA2 (0.56) | ALDH1A1HPGDHSD17B10MEP1BCA2 | |
| SCHEMBL163450 | 0.83 | HTT (0.51) | ALDH1A1HPGDHSD17B10MEP1BCA2 | |
| SCHEMBL16799605 | 0.80 | PTGDR2 (0.46) | ALDH1A1HPGDHSD17B10AKR1B1 | |
| SCHEMBL2665987 | 0.80 | KMT2A (0.53) | ALDH1A1HSD17B10NPSR1KDM4ERORC | |
| SCHEMBL28906881 | 0.79 | CA2 (0.53) | ALDH1A1CA2RORCKMT2A | |
| SCHEMBL14744352 | 0.79 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4EGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077372-B1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2019-02-06 | — | — | EP | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| EP-3077372-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Cel Models IP B.V. (NL) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015082533-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2015-06-11 | — | — | WO | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012028100-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028100-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| EP-2168962-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | ALDH1A1 1595/4885HPGD 1237/4885HSD17B10 531/4885 |
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | ALDH1A1 1438/4885HPGD 1549/4885HSD17B10 3716/4885 |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | RORC, RORA, RORB | ALDH1A1 1054/4885HPGD 4602/4885HSD17B10 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.